- Approval Id
- 0d4c95acbda4c070
- Drug Name
- ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCG
- Product Name
- ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCG
- Approval Number
- SIN16147P
- Approval Date
- 2021-04-07
- Registrant
- NOVARTIS (SINGAPORE) PTE LTD
- Licence Holder
- NOVARTIS (SINGAPORE) PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- POWDER, METERED
- Dosage
- <p><strong>3 Dosage regimen and administration</strong></p>
<p><strong>Dosage regimen</strong></p>
<p><strong>General target population</strong></p>
<p>Inhalation of the content of one capsule of Atectura Breezhaler 150/80 micrograms once daily is recommended in patients who require a combination of a long-acting beta<sub>2</sub>-agonist and a low dose of inhaled corticosteroid.</p>
<p>Inhalation of the content of one capsule of Atectura Breezhaler 150/160 micrograms or 150/320 micrograms once daily is recommended in patients who require a combination of a long-acting beta<sub>2</sub>-agonist and a medium or high dose of inhaled corticosteroid.</p>
<p>Patients usually experience an improvement in lung function within 5 minutes of inhaling Atectura Breezhaler. However, the patient should be informed that regular daily use is necessary to maintain control of asthma symptoms and that use should be continued even when asymptomatic.</p>
<p>The maximum recommended dose is Atectura Breezhaler 150/320 micrograms once daily.</p>
<p><strong>Special populations</strong></p>
<p><strong>Renal impairment</strong></p>
<p>No dose adjustment is required in patients with renal impairment.</p>
<p><strong>Hepatic impairment</strong></p>
<p>No dose adjustment is required in patients with mild or moderate hepatic impairment. No data are available for Atectura Breezhaler in subjects with severe hepatic impairment, therefore Atectura Breezhaler should be used in these patients only if the expected benefit outweighs the potential risk (see section 10 Clinical pharmacology – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
<p><strong>Pediatric patients (below 12 years)</strong></p>
<p>Atectura Breezhaler may be used in pediatric patients (12 years of age and older) at the same posology as in adults. The safety and efficacy of Atectura Breezhaler in pediatric patients below 12 years of age have not been established.</p>
<p><strong>Geriatric patients (65 years or above)</strong></p>
<p>No dose adjustment is required in elderly patients 65 years of age or older (see section 10 Clinical pharmacology – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
<p><strong>Method of administration</strong></p>
<p>For inhalation use only. Atectura Breezhaler capsules must not be swallowed.</p>
<p>Patients should be instructed on how to administer the medicinal product correctly. Patients who do not experience improvement in breathing should be asked if they are swallowing the capsule rather than inhaling it.</p>
<p>The capsules must be administered only using the Atectura Breezhaler inhaler. The inhaler provided with each new prescription should be used.</p>
<p>Atectura Breezhaler should be administered at the same time of the day each day. It can be administered irrespective of the time of the day.</p>
<p>The capsules must always be stored in the blister to protect from moisture and light, and only removed immediately before use (see section 13 Pharmaceutical information – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
<p>After inhalation, patients should rinse their mouth with water without swallowing.</p>
<p>If a dose is missed, it should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.</p>
- Route Of Administration
- RESPIRATORY (INHALATION)
- Indication Info
- <p><strong>2 Indications</strong></p>
<p>Atectura Breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta<sub>2</sub>-agonist and inhaled corticosteroid is appropriate.</p>
- Contraindications
- <p><strong>4 Contraindications</strong></p>
<p>Atectura Breezhaler is contraindicated in patients with hypersensitivity to any of the active substances or excipients.</p>
- Atc Code
- R03AK14
- Atc Item Name
- indacaterol and mometasone
- Pharma Manufacturer Name
- NOVARTIS (SINGAPORE) PTE LTD
